1. Market Research
  2. > Biotechnology Market Trends
  3. > Indus Biotech Private Limited - Product Pipeline Review - 2013

Indus Biotech Private Limited - Product Pipeline Review - 2013

  • July 2013
  • -
  • Global Markets Direct
  • -
  • 29 pages

Indus Biotech Private Limited - Product Pipeline Review - 2013

Summary

Global Markets Direct’s pharmaceuticals report, “Indus Biotech Private Limited - Product Pipeline Review - 2013” provides data on the Indus Biotech Private Limited’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Indus Biotech Private Limited’s corporate website, SEC filings, investor presentations and featured press releases, both from Indus Biotech Private Limited and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Indus Biotech Private Limited - Brief Indus Biotech Private Limited overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Indus Biotech Private Limited human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Indus Biotech Private Limited with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Indus Biotech Private Limited’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Indus Biotech Private Limited’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Indus Biotech Private Limited in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Indus Biotech Private Limited’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Indus Biotech Private Limited.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Indus Biotech Private Limited and identify potential opportunities in those areas.

Table Of Contents

Indus Biotech Private Limited - Product Pipeline Review - 2013
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Indus Biotech Private Limited Snapshot 5
Indus Biotech Private Limited Overview 5
Key Information 5
Key Facts 5
Indus Biotech Private Limited - Research and Development Overview 6
Key Therapeutic Areas 6
Indus Biotech Private Limited - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Indus Biotech Private Limited - Pipeline Products Glance 10
Indus Biotech Private Limited - Early Stage Pipeline Products 10
Preclinical Products/Combination Treatment Modalities 10
Indus Biotech Private Limited - Drug Profiles 11
INDUS-810 11
Product Description 11
Mechanism of Action 11
RandD Progress 11
INDUS-815B 12
Product Description 12
Mechanism of Action 12
RandD Progress 12
INDUS-815C 13
Product Description 13
Mechanism of Action 13
RandD Progress 13
INDUS-820 14
Product Description 14
Mechanism of Action 14
RandD Progress 14
INDUS-82010 15
Product Description 15
Mechanism of Action 15
RandD Progress 15
INDUS-82020 16
Product Description 16
Mechanism of Action 16
RandD Progress 16
INDUS-82030 17
Product Description 17
Mechanism of Action 17
RandD Progress 17
INDUS-83030 18
Product Description 18
Mechanism of Action 18
RandD Progress 18
INDUS-860 19
Product Description 19
Mechanism of Action 19
RandD Progress 19
INDUS-CA1 20
Product Description 20
Mechanism of Action 20
RandD Progress 20
Indus Biotech Private Limited - Pipeline Analysis 21
Indus Biotech Private Limited - Pipeline Products by Therapeutic Class 21
Indus Biotech Private Limited - Pipeline Products By Target 23
Indus Biotech Private Limited - Pipeline Products By Mechanism of Action 24
Indus Biotech Private Limited - Dormant Projects 26
Indus Biotech Private Limited - Locations And Subsidiaries 27
Head Office 27
Appendix 28
Methodology 28
Coverage 28
Secondary Research 28
Primary Research 28
Expert Panel Validation 28
Contact Us 29
Disclaimer 29

List of Tables

Indus Biotech Private Limited, Key Information 5
Indus Biotech Private Limited, Key Facts 5
Indus Biotech Private Limited - Pipeline by Indication, 2013 7
Indus Biotech Private Limited - Pipeline by Stage of Development, 2013 8
Indus Biotech Private Limited - Monotherapy Products in Pipeline, 2013 9
Indus Biotech Private Limited - Preclinical, 2013 10
Indus Biotech Private Limited - Pipeline By Therapeutic Class, Select 22
Indus Biotech Private Limited - Pipeline By Target, Select 23
Indus Biotech Private Limited - Pipeline Products By Mechanism of Action, Select 25
Indus Biotech Private Limited - Dormant Developmental Projects,2013 26

List of Figures

Indus Biotech Private Limited - Pipeline by Indication, 2013 7
Indus Biotech Private Limited - Pipeline by Stage of Development, 2013 8
Indus Biotech Private Limited - Monotherapy Products in Pipeline, 2013 9
Indus Biotech Private Limited - Pipeline By Therapeutic Class, 2013 21
Indus Biotech Private Limited - Pipeline Products By Mechanism of Action, Select 24

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Glycoprotein 41 (gp41) - Pipeline Review, H2 2016

Glycoprotein 41 (gp41) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • October 2016
  • by Global Markets Direct

Glycoprotein 41 (gp41) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Glycoprotein 41 (gp41) - Pipeline Review, H2 2016’, provides in depth analysis on Glycoprotein 41 (gp41) targeted ...

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Pipeline Review, H2 2016

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Cellular Tumor Antigen p53 (Tumor Suppresso ...

Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Pipeline Review, H2 2016

Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • October 2016
  • by Global Markets Direct

Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Cytotoxic T Lymphocyte Protein 4 (Cytotoxic ...

Tetanus - Pipeline Review, H2 2016

September 2016 $ 2000

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.